- Home
- MVF vs URGN Comparison
MVF vs URGN Comparison
Compare MVF & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVF
- URGN
- Stock Information
- Founded
- MVF 1988
- URGN 2004
- Country
- MVF United States
- URGN United States
- Employees
- MVF N/A
- URGN N/A
- Industry
- MVF Investment Bankers/Brokers/Service
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MVF Finance
- URGN Health Care
- Exchange
- MVF Nasdaq
- URGN Nasdaq
- Market Cap
- MVF 465.2M
- URGN 547.1M
- IPO Year
- MVF N/A
- URGN 2017
- Fundamental
- Price
- MVF $7.18
- URGN $11.18
- Analyst Decision
- MVF
- URGN Strong Buy
- Analyst Count
- MVF 0
- URGN 5
- Target Price
- MVF N/A
- URGN $44.50
- AVG Volume (30 Days)
- MVF 162.8K
- URGN 351.4K
- Earning Date
- MVF 01-01-0001
- URGN 11-06-2024
- Dividend Yield
- MVF 4.11%
- URGN N/A
- EPS Growth
- MVF N/A
- URGN N/A
- EPS
- MVF N/A
- URGN N/A
- Revenue
- MVF N/A
- URGN $89,363,000.00
- Revenue This Year
- MVF N/A
- URGN $13.39
- Revenue Next Year
- MVF N/A
- URGN $45.06
- P/E Ratio
- MVF N/A
- URGN N/A
- Revenue Growth
- MVF N/A
- URGN 15.64
- 52 Week Low
- MVF $5.85
- URGN $10.60
- 52 Week High
- MVF $7.19
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- MVF 33.85
- URGN 36.66
- Support Level
- MVF $7.16
- URGN $11.08
- Resistance Level
- MVF $7.43
- URGN $11.67
- Average True Range (ATR)
- MVF 0.07
- URGN 0.51
- MACD
- MVF -0.03
- URGN -0.10
- Stochastic Oscillator
- MVF 7.32
- URGN 7.50
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.